Mieloproliferatív neopláziák: vizsgálatok itt: Románia
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 4. fázisTaking peopleAsciminib Roll-over Study
- Where
- Bucharest, Cluj-Napoca, Timisoara
- Életkor
- 7 év to 100 év
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - 3. fázisNot yet taking people in RomániaA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Bucharest, Cluj-Napoca, Craiova, Timisoara
- Életkor
- 18 év and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - 1/2. fázisNot yet taking people in RomániaA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Brasov
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - 2. fázisFut, nem toborozA Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
- Where
- Bucharest, Craiova, Iași
- Életkor
- 18 év and over
- People
- 38 worldwide
- Run by
- Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 - 3. fázisTaking peopleAdding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
- Where
- Brasov, Bucharest, Cluj-Napoca, Oradea, Târgu Mureş
- Életkor
- 18 év and over
- People
- 126 worldwide
- Run by
- Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 - No phaseTaking peopleClinical Epidemiology in Contemporary Patients With Myelofibrosis.
- Where
- Bucharest
- Életkor
- 18 év to 100 év
- People
- 617 worldwide
- Run by
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06533813 - 2. fázisTaking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Bucharest, Craiova, Iași
- Életkor
- 18 év and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - 3. fázisTaking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Brasov, Bucharest, Cluj-Napoca, Oradea, Târgu Mureş
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135